Skip to main content
Premium Trial:

Request an Annual Quote

Genentech Subscribes to Gene Logic s BioExpress Database

NEW YORK, Feb 15 - Gene Logic said Thursday that Genentech subscribed to its BioExpress database, making Genetech the seventh customer for BioExpress.

Financial terms of the multi-year subscription were not disclosed, but Gene Logic has said previously that subscriptions are typically for three years and can cost up to $4 million per year for pharmaceutical companies and $2 million a year for biotechs.

The BioExpress database contains gene expression information for normal and diseased human tissues, tissues from model animal systems, and human and animal cell lines for use in drug target identification.

In addition to BioExpress, Gene Logic sells subscriptions to ToxExpress, which offers data on the effects of more than 10 toxic compounds on the liver, kidney, bone marrow, and heart of animals. The company has eight subscribers for this database.

GeneLogic of Gaithersburg, Md., is also planning to launch in 2001 a new database, PharmExpress, which will offer information about the effect pharmaceuticals have on gene expression.

Genetech also subscribes to Incyte Genomics databases.

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.